Analysts Predict 15% Gains Ahead For VONV
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Should l Buy LEG?
Source: NASDAQ.COM
Vanguard Russell 1000 Value ETF Analysis: The Vanguard Russell 1000 Value ETF (VONV) has an implied analyst target price of $95.30 per unit, indicating a potential upside of 14.99% from its current trading price of $82.88.
Notable Holdings with Upside Potential: Key holdings within VONV, such as Leggett & Platt, Inc., NOV Inc, and Boston Scientific Corp., show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEG
Wall Street analysts forecast LEG stock price to rise
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 11.370
Low
11.00
Averages
12.00
High
13.00
Current: 11.370
Low
11.00
Averages
12.00
High
13.00
About LEG
Leggett & Platt, Incorporated is a diversified manufacturer that designs and produces a variety of engineered components and products that can be found in homes and automobiles. Its segments include Bedding Products, Specialized Products and Furniture, Flooring & Textile Products. The Bedding Products segment supplies a variety of components used by bedding manufacturers, as well as produces private label finished mattresses and adjustable bed bases. This segment is also vertically integrated into the production and supply of specialty foam chemicals, steel rod, and drawn steel wire to its own operations and to external customers. Specialized Products segment supplies lumbar support systems, seat suspension systems, motors and actuators, and control cables used by automotive manufacturers. The Furniture, Flooring & Textile Products segment supplies a range of components for residential and work furniture manufacturers, as well as select lines of private label finished furniture.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Leggett & Platt to Announce Q1 Earnings on May 7
- Earnings Announcement: Leggett & Platt (LEG) is set to release its Q1 earnings on May 7 before market open, with a consensus EPS estimate of $0.24, indicating stable profitability year-over-year.
- Revenue Decline Expected: The revenue estimate for Q1 stands at $946.79 million, reflecting a 5.3% year-over-year decline, suggesting potential pressure on market demand that the company must address.
- Historical Performance Review: Over the past two years, LEG has only beaten EPS and revenue estimates 25% of the time, indicating a lack of consistency in meeting earnings forecasts, which could impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and two downward revisions, while revenue estimates have experienced two upward and two downward revisions, reflecting analyst divergence on the company's future performance, potentially affecting stock price volatility.
See More
Leggett & Platt Misses Q1 Earnings Expectations
- Earnings Miss: Leggett & Platt reported a Q1 non-GAAP EPS of $0.15, missing expectations by $0.09, indicating a significant decline in profitability that may undermine investor confidence.
- Revenue Decline: The company posted revenues of $918 million, an 8.2% year-over-year decrease, falling short of market expectations by $28.79 million, reflecting pressures from weak market demand and intensified competition.
- Guidance Withdrawal: Leggett & Platt has withdrawn its previously issued 2026 guidance due to the pending acquisition by Somnigroup International, which could increase uncertainty regarding future performance among investors.
- Market Reaction: The earnings miss and guidance withdrawal may trigger negative market reactions towards Leggett & Platt's stock, prompting investors to closely monitor the acquisition's progress and its strategic implications for the company.
See More
Leggett & Platt Reports Decline in Q1 Earnings
- Earnings Decline: Leggett & Platt reported a net income of $20 million for Q1, translating to $0.14 per share, which is a significant drop from last year's $30.6 million and $0.22 per share, indicating mounting pressure on profitability.
- Adjusted Earnings: The company reported adjusted earnings of $0.15 per share, slightly above the GAAP figure, yet still reflects weakened profitability that could impact investor confidence moving forward.
- Revenue Drop: Revenue for the quarter fell to $918.2 million, a 10.2% decrease from $1.022 billion last year, highlighting the effects of soft market demand and intensified competition.
- Uncertain Market Outlook: The dual decline in revenue and earnings may pose challenges for the company's future market performance, prompting investors to closely monitor its strategic responses and signs of market recovery.
See More
Leggett & Platt Reports 10% Decline in Q1 Sales Amid Market Challenges
- Sales Performance Decline: Leggett & Platt reported first-quarter sales of $918 million, a 10% decrease year-over-year, reflecting weak demand in the U.S. mattress market, particularly in residential sectors, leading to overall performance falling short of expectations.
- EBIT and Profit Drop: The first-quarter EBIT was $45 million, down 29% from $63 million in the same period last year, with EBIT margin declining from 6.2% to 4.8%, indicating a dual impact from cost pressures and insufficient market demand.
- Merger Agreement Progress: Leggett has signed a merger agreement with Somnigroup, anticipated to close by the end of 2026, which will provide shareholders with an opportunity to participate in future growth, highlighting the company's commitment to long-term strategic goals.
- Increased Cost Pressures: The company faces heightened cost pressures due to rising transportation costs and chemical prices driven by the war in Iran, and while Leggett is implementing product and sourcing measures to mitigate these impacts, future profitability remains a concern.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between McCormick & Company and Unilever's Foods business, where McCormick shareholders will own 35% of the combined company upon closing, potentially impacting shareholder rights and market competition.
- Shareholder Rights Protection: Leggett & Platt is selling to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per share of Leggett & Platt, resulting in shareholders owning approximately 9% of the combined company, prompting Halper Sadeh LLC to remind shareholders of their legal rights.
- Acquisition Price Dispute: Organon & Co. is being sold to Sun Pharmaceutical Industries for $14.00 per share, with Halper Sadeh LLC potentially seeking to increase the acquisition price to ensure shareholders receive fair compensation.
- Internal Transaction Review: Kennedy-Wilson Holdings is being sold for $10.90 per share in cash to a consortium led by executives, with Halper Sadeh LLC possibly requesting additional information and disclosures to protect shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
Leggett & Platt to Announce Q1 Earnings on May 7
- Earnings Announcement: Leggett & Platt (LEG) is set to release its Q1 earnings on May 7 before market open, with a consensus EPS estimate of $0.24, indicating stable profitability year-over-year.
- Revenue Decline Expected: The revenue estimate for Q1 stands at $946.79 million, reflecting a 5.3% year-over-year decline, suggesting potential pressure on market demand that the company must address.
- Historical Performance Review: Over the past two years, LEG has only beaten EPS and revenue estimates 25% of the time, indicating a lack of consistency in meeting earnings forecasts, which could impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and two downward revisions, while revenue estimates have experienced two upward and two downward revisions, reflecting analyst divergence on the company's future performance, potentially affecting stock price volatility.
See More
Leggett & Platt Misses Q1 Earnings Expectations
- Earnings Miss: Leggett & Platt reported a Q1 non-GAAP EPS of $0.15, missing expectations by $0.09, indicating a significant decline in profitability that may undermine investor confidence.
- Revenue Decline: The company posted revenues of $918 million, an 8.2% year-over-year decrease, falling short of market expectations by $28.79 million, reflecting pressures from weak market demand and intensified competition.
- Guidance Withdrawal: Leggett & Platt has withdrawn its previously issued 2026 guidance due to the pending acquisition by Somnigroup International, which could increase uncertainty regarding future performance among investors.
- Market Reaction: The earnings miss and guidance withdrawal may trigger negative market reactions towards Leggett & Platt's stock, prompting investors to closely monitor the acquisition's progress and its strategic implications for the company.
See More
Leggett & Platt Reports Decline in Q1 Earnings
- Earnings Decline: Leggett & Platt reported a net income of $20 million for Q1, translating to $0.14 per share, which is a significant drop from last year's $30.6 million and $0.22 per share, indicating mounting pressure on profitability.
- Adjusted Earnings: The company reported adjusted earnings of $0.15 per share, slightly above the GAAP figure, yet still reflects weakened profitability that could impact investor confidence moving forward.
- Revenue Drop: Revenue for the quarter fell to $918.2 million, a 10.2% decrease from $1.022 billion last year, highlighting the effects of soft market demand and intensified competition.
- Uncertain Market Outlook: The dual decline in revenue and earnings may pose challenges for the company's future market performance, prompting investors to closely monitor its strategic responses and signs of market recovery.
See More
Leggett & Platt Reports 10% Decline in Q1 Sales Amid Market Challenges
- Sales Performance Decline: Leggett & Platt reported first-quarter sales of $918 million, a 10% decrease year-over-year, reflecting weak demand in the U.S. mattress market, particularly in residential sectors, leading to overall performance falling short of expectations.
- EBIT and Profit Drop: The first-quarter EBIT was $45 million, down 29% from $63 million in the same period last year, with EBIT margin declining from 6.2% to 4.8%, indicating a dual impact from cost pressures and insufficient market demand.
- Merger Agreement Progress: Leggett has signed a merger agreement with Somnigroup, anticipated to close by the end of 2026, which will provide shareholders with an opportunity to participate in future growth, highlighting the company's commitment to long-term strategic goals.
- Increased Cost Pressures: The company faces heightened cost pressures due to rising transportation costs and chemical prices driven by the war in Iran, and while Leggett is implementing product and sourcing measures to mitigate these impacts, future profitability remains a concern.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between McCormick & Company and Unilever's Foods business, where McCormick shareholders will own 35% of the combined company upon closing, potentially impacting shareholder rights and market competition.
- Shareholder Rights Protection: Leggett & Platt is selling to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per share of Leggett & Platt, resulting in shareholders owning approximately 9% of the combined company, prompting Halper Sadeh LLC to remind shareholders of their legal rights.
- Acquisition Price Dispute: Organon & Co. is being sold to Sun Pharmaceutical Industries for $14.00 per share, with Halper Sadeh LLC potentially seeking to increase the acquisition price to ensure shareholders receive fair compensation.
- Internal Transaction Review: Kennedy-Wilson Holdings is being sold for $10.90 per share in cash to a consortium led by executives, with Halper Sadeh LLC possibly requesting additional information and disclosures to protect shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
